Abera is a Swedish biotech company headquartered in Stockholm, Sweden. Abera is committed to becoming a world-leading company in innovative vaccine technologies.

MANAGEMENT TEAM

Anders Ericson

CEO, Chairman of the Board

Anders Ericson has worked in several positions within the financial industry for more than 18 years. He is the owner and CEO of Smallcap.se, which is a financial communications firm specializing in life science companies.

Joen Luirink

CSO, Member of the Board

Prof. Luirink has more than 35 years of experience in Biochemistry and Molecular Microbiology and authored over 140 original scientific publications in peer-reviewed journals. Prof. Luirink specializes in protein trafficking in bacteria. He is currently head of the Department of Molecular Microbiology at VU University Amsterdam, and serves as the CSO of Abera.

BOARD OF DIRECTORS

Anders Ericson

CEO, Chairman of the Board

Anders Ericson has worked in several positions within the financial industry for more than 18 years. He is the owner and CEO of Smallcap.se, which is a financial communications firm specializing in life science companies.

Joen Luirink

CSO, Member of the Board

Prof. Luirink has more than 35 years of experience in Biochemistry and Molecular Microbiology and authored over 140 original scientific publications in peer-reviewed journals. Prof. Luirink specializes in protein trafficking in bacteria. He is currently head of the Department of Molecular Microbiology at VU University Amsterdam, and serves as the CSO of Abera.

Alf Lindberg

Member of the Board

Prof. Alf Lindberg has held the CSO position and Director of R&D position at Wyeth Vaccines and Sanofi Pasteur. He has extensive experience in vaccine development and is also a former professor in Clinical Bacteriology at Karolinska Institute in Stockholm. Prof. Lindberg is active as board member in several biotech and vaccine development companies worldwide.

ADVISORY BOARD

Carlos A. Guzmán

Member of the Advisory board

Prof. Guzmán (MD, PhD) is head of the Dept. Vaccinology and Applied Microbiology at the Helmholtz Centre for Infection Research in Braunschweig, Germany. Also, he is appointed as APL-professor at the Hannover Medical School. His work was instrumental for developing new adjuvants and antigen delivery systems, leading to more than 200 publications.

 

Jan-Willem de Gier

Member of the Advisory board

Prof. de Gier is group leader at the Dept. of Biochemistry and Biophysics of Stockholm University. His work focuses on the engineering of bacteria for recombinant protein production. Prof. de Gier co-founded the successful biotech start-up Xbrane Bioscience, now Xbrane Biopharma.

Samuel Wagner

Member of the Advisory board

Prof. dr. Wagner is Professor of Infection Biology and Head of the Section of Cellular and Molecular Microbiology of the Eberhard Karls University Tübingen, Germany. He specializes in protein export pathways in pathogenic bacteria. Prof. dr. Wagner is a co-founder of Xbrane Biopharma and predecessor Xbrane Bioscience.

Marien de Jonge

Member of the Advisory board

Prof. Marien de Jonge is Head of the Section Pediatric Infectious Diseases at the Radboud University Medical Centre. Previously he held the position of Project leader at vaccine producer Nobilon (MSD). Through his role at RUMC Prof. de Jonge has been a partner to Abera on the development of a pneumococcal vaccine since 2012.